Teen Substance Use Disorders: Warning Signs, Assessment, and Care
Author: Angela Bogdanova · Published: October 19, 2026 · Editorial Policy
Research cluster: Substance Use Disorders and Addiction Recovery · Written by Artificial Sapiens
Teen substance use disorders require a developmental, clinical, and safety-focused approach. Alcohol, cannabis, nicotine, prescription medications, opioids, stimulants, inhalants, and other psychoactive substances can create harm before a young person meets diagnostic criteria for a substance use disorder. Warning signs are reasons for a careful conversation and assessment, not proof that a teenager has an addiction. Effective care identifies immediate hazards, asks directly about use and functioning, protects the therapeutic relationship, involves supportive adults when appropriate, and offers evidence-informed treatment matched to the young person's circumstances. The American Academy of Child and Adolescent Psychiatry's clinical practice guideline provides the contemporary evidence framework for psychosocial and opioid medication treatments in adolescents and young adults.
This scientific guide explains what counts as risky use or a substance use disorder in adolescence, how warning signs differ from diagnostic criteria, what validated screening tools can and cannot establish, when medical attention is urgent, how confidential assessment and family participation work, and what clinical trials and systematic reviews actually show about treatment and recovery. The focus is care for teenagers; substance-specific diagnostic algorithms and detailed treatment pharmacology belong to the corresponding specialist scientific articles.
What Is a Teen Substance Use Disorder?
A substance use disorder (SUD) is a clinically significant pattern of substance involvement associated with problems such as impaired control, hazardous use, continued use despite consequences, or interference with important obligations. DSM-5-TR diagnoses rely on substance-specific criteria evaluated over a defined period, commonly 12 months; clinicians assess the number of qualifying criteria and clinical context rather than treating a single episode or laboratory finding as a diagnosis. The ICD-11 organizes related conditions with its own distinctions, including harmful patterns and dependence. Developmentally informed evaluation asks whether symptoms reflect the substance, the young person's circumstances, and an enduring pattern of impairment. See the general diagnostic foundations of substance use disorders for the wider classification framework.
Substance use means exposure or consumption. Risky or hazardous use describes behavior associated with an increased probability of harm, including using intoxicants before driving or riding with an impaired driver. Substance misuse is a contextual term often used for using a prescription medication other than prescribed or using a substance in a harmful way; it is not itself a standardized diagnosis. Addiction describes a clinical pattern of impaired control and persistence despite significant harm, and overlaps with moderate or severe substance use disorders without being a universal synonym for any experimentation. Tolerance is a reduced response to a given exposure; withdrawal is a syndrome following reduction or cessation in a physiologically adapted person; physical dependence is adaptation that can occur during legitimate medical treatment. Neither tolerance nor withdrawal alone establishes compulsive use. These distinctions matter when a teen receives prescribed stimulants, opioids, or sedative medications for a legitimate indication.
Why Adolescence Changes the Clinical Picture
Adolescence includes rapid changes in social identity, emotional regulation, peer affiliation, sleep, school obligations, autonomy, and decision-making. Reward sensitivity and executive control develop in interacting systems across adolescence and young adulthood. Research connects earlier substance exposure with greater later disorder risk, but these associations reflect multiple pathways, including shared genetic vulnerability, family and neighborhood context, prior behavior, access to substances, and bidirectional effects. Developmental neuroscience supports additional caution about exposure during this period; it does not establish that every teenager who uses a substance will develop enduring brain injury or addiction.
A youth-focused assessment attends to social and developmental tasks that may not appear on adult questionnaires: attending school, learning, sports, friendships, driving, online purchasing, family trust, exploitation risk, and transitions in living arrangements. It also considers autism, ADHD, learning disabilities, cognitive differences, disability accommodations, language, cultural context, and exposure to violence without presuming any of these characteristics is evidence of drug use. The 2026 adolescent and transition-aged youth ASAM Criteria formalize youth-guided and family-informed multidimensional care across settings.
Warning Signs: What Parents, Caregivers, and Clinicians May Notice
Changes in behavior, school, and relationships
Warning signs can include a new pattern of missing school, declining academic performance, abandoning important commitments, persistent unexplained absences, risky driving, repeated intoxication-related incidents, conflicts about money, or spending unusually long periods obtaining or recovering from substances. Changes in peer groups or a stronger desire for privacy may coexist with use, but they are also common developmental experiences. A pattern gains clinical significance when repeated observations are connected to credible information about substance exposure, impairment, safety concerns, or the young person's own account.
Physical and psychological changes
Intoxication may produce altered coordination, slowed speech, unusual sleepiness, agitation, confusion, impaired attention, or changes in pupil size, depending on the substance and timing. Recurrent nausea, sleep disruption, appetite changes, injuries, coughing, or worsening mood can raise concerns but are not substance-specific. A teenager may report cravings, discomfort when unable to use, escalating consumption, attempts to stop that do not last, or using to manage anxiety, loneliness, trauma reminders, or insomnia. These are prompts to ask about distress and safety as well as substance exposure.
Environmental indicators and digital access
Unexplained pills, vape cartridges, powders, alcohol containers, drug paraphernalia, or secretive purchases can justify calm inquiry. Counterfeit pills and products sold through digital channels add the risk that the declared contents differ from actual ingredients. CDC information on illegally manufactured fentanyl describes how counterfeit tablets can contain fentanyl even when marketed as other medications. A found object or changed phone behavior should never be treated as a substitute for clinical conversation and corroborated assessment.
What warning signs cannot establish
Fatigue, irritability, secrecy, social withdrawal, mood shifts, academic difficulty, and changes in sleep are also associated with depression, anxiety, bullying, trauma, chronic illness, grief, neurodevelopmental conditions, medication effects, and ordinary life transitions. Clinicians investigate competing explanations and can identify more than one contributing problem. A negative disclosure from a frightened teenager does not settle the clinical question; nor does a caregiver's suspicion justify imposing a psychiatric label. The strongest foundation is an open, specific chronology: what changed, when, what was observed directly, and what risks are present now.
When Substance Use Is a Medical Emergency
Possible opioid overdose
Slow, absent, or irregular breathing, inability to wake, gurgling or snoring-like respirations in an unresponsive person, severe cyanosis, or collapse requires immediate emergency services. An opioid overdose can occur without a known history of addiction, particularly after exposure to counterfeit pills. Give naloxone when opioid overdose is suspected and it is available, following the product instructions, and start dispatcher-guided rescue breathing or CPR as indicated. Naloxone can wear off before the opioid, and additional emergency medical evaluation remains necessary even if the person awakens. Avoid assuming that a teenager is merely asleep or letting them “sleep it off.” CDC overdose prevention guidance supports naloxone access and rapid response.
Severe intoxication, poisoning, and other urgent syndromes
Seizures, severe confusion, extreme agitation with overheating, chest pain, serious breathing difficulty, fainting, severe dehydration, hallucinations with dangerous behavior, or suspected ingestion of an unknown toxic substance require emergency assessment. Alcohol poisoning can produce vomiting with impaired consciousness, slowed breathing, hypothermia, and aspiration. Stimulant toxicity can involve hyperthermia, dangerous cardiovascular effects, and psychosis. Co-use of alcohol, sedatives, and opioids increases concern for respiratory depression. The immediate decision concerns physical safety and medical stabilization, not whether a substance use disorder has already been diagnosed.
Withdrawal, psychiatric crisis, and self-harm
After regular heavy exposure, abrupt cessation of alcohol or benzodiazepines can cause seizures or delirium and may be life-threatening. Adolescents with physiological dependence need individualized medical advice rather than unsupervised detoxification. Opioid withdrawal is often intensely distressing and warrants medical care; a return to opioid use after reduced tolerance brings elevated overdose risk. Direct suicidal statements, an attempt, a plan or intent to die, or inability to maintain immediate safety requires urgent emergency or crisis evaluation regardless of the substance involved. Intoxication can complicate reliable psychiatric examination; clinicians reassess after stabilization and arrange continued safety support. For the distinct clinical interface, see Substance Use Disorders and Suicide Risk.
Screening Is the Entry Point, Not the Diagnosis
Screening asks whether use or risk may be present, usually with brief standardized questions. A positive screen calls for a supportive assessment; it does not declare the teenager “addicted.” A negative screen does not outweigh compelling evidence of acute intoxication or danger. Screening is most informative when adolescents understand confidentiality and can answer privately, without fearing immediate punishment for an honest response. The American Academy of Pediatrics clinical report, reaffirmed in 2023, describes screening, brief intervention, and referral to treatment (SBIRT) as a practical pediatric-care framework.
CRAFFT and age-appropriate tools
CRAFFT is a brief validated adolescent substance-use risk instrument. It asks about circumstances and consequences of use, including riding in a car with an impaired driver, using to relax, using alone, forgetting events, concerns expressed by friends or family, and getting into trouble. A higher score increases the likelihood that further diagnostic assessment will identify a disorder, but thresholds depend on age, instrument version, setting, and underlying prevalence. The foundational Knight and colleagues validation study compared the screen with structured clinical assessment, supporting its use as a triage instrument rather than a stand-alone diagnostic test. Newer CRAFFT versions and tobacco/vaping questions should be selected in their current validated forms.
The NIAAA youth alcohol screening guide proposes short, age-sensitive screening for ages 9 through 18, with a focus on the adolescent's drinking and peer drinking. It can detect early alcohol-related risk before a disorder develops. Some adult-oriented instruments, such as AUDIT-C and DAST-10, have different validation histories and cutoffs, so clinicians should not automatically transplant adult thresholds into younger populations. Screens for nicotine/vaping, cannabis, opioids, and other substances are selected according to the relevant exposure, age, and clinical setting.
Why professional recommendations differ
The AAP encourages routine identification and counseling opportunities, whereas the US Preventive Services Task Force issued an “I statement” for universal screening for unhealthy drug use among ages 12–17 because evidence was insufficient to determine its net benefit or harm in primary care. It also found insufficient evidence to assess the balance of benefits and harms for alcohol screening and brief counseling in this age group. An I statement records an evidence gap regarding the preventive service's population-level outcomes; it does not mean that clinicians should disregard reported use, intoxication, safety risks, or requests for help. Both perspectives reinforce the importance of implementing screening with meaningful assessment and access to care.
How Clinicians Assess a Teenager Who May Be Using Substances
A full assessment begins with immediate safety and then develops a confidential, nonjudgmental history. The clinician asks what substances have been used, how often, how much when known, by which route, when last used, whether products may be counterfeit, whether alcohol or other drugs were combined, and what changed in sleep, mood, school, relationships, and physical health. Questions cover impaired control, craving, tolerance, withdrawal, unsuccessful efforts to cut down, overdose or injury, driving, sexual health, access to prescribed medicines, and risks at home. The narrative should distinguish first experimentation, intermittent risky use, escalating recurrent use, and clinically significant disorder.
Diagnosis and differential diagnosis
Diagnostic evaluation determines whether criteria are met for a particular substance class, over the relevant duration, with clinically meaningful impairment. Adolescents may have acute harmful exposure without an established SUD, and may meet criteria despite appearing outwardly functional. Developmental interpretation is especially important when adult-oriented diagnostic language captures conflicts that could also reflect family or school circumstances. Clinicians distinguish intoxication, withdrawal, substance-induced psychiatric symptoms, preexisting mental health disorders, trauma responses, sleep conditions, and medical causes. Assessment includes physical examination and appropriate diagnostic testing when justified; test choice depends on the clinical question.
Mental health, trauma, and neurodevelopment
Depression, anxiety, ADHD, eating disorders, PTSD, psychotic symptoms, self-harm, sleep disruption, bullying, family violence, and adverse childhood experiences may precede, follow, or coexist with substance use. Association does not resolve causal order. A clinician builds a timeline that includes symptom onset before and after substance exposure and during periods of reduced use. The teen's developmental stage, language, experiences of discrimination, learning needs, and emotional safety influence disclosure and treatment participation. Emergency suicidal or psychotic symptoms receive their own assessment even when substance use is present. For a separately owned scientific analysis of a related syndrome, see Anxiety and Substance Use.
Toxicology and laboratory testing
Urine or other toxicology tests may help answer a narrow question about certain recent exposures, monitoring, or suspected poisoning. Detection windows, false positives, false negatives, cross-reactivity, missing substances on standard panels, and uncertainty about dose or impairment limit interpretation. A positive test cannot by itself diagnose addiction, establish the frequency of use, or prove impairment at a specific time. A negative result cannot exclude fentanyl analogs or other substances not covered by the panel. Consent, clinical utility, privacy, and the possibility of damaging trust must be considered carefully; indiscriminate or punitive testing is a poor substitute for comprehensive evaluation.
Confidentiality and caregiver involvement
Adolescents disclose more accurately when the boundaries of confidentiality are explained before sensitive questions. Clinicians discuss which information can remain private, what records or portal access may reveal, and the circumstances under which immediate safety or applicable law requires involving a caregiver or protecting the young person. Rules governing minor consent, substance treatment records, school disclosures, and emergency exceptions differ by jurisdiction and service. Promising unconditional secrecy is misleading. Ideally, the clinician works collaboratively with the teen to include a safe caregiver or trusted adult, and responds carefully when the home environment itself is unsafe.
What Makes an Assessment Truly Developmentally Appropriate?
A useful interview takes place partly with the teenager alone and, when safe, partly with a caregiver. The clinician describes confidentiality in plain language, uses neutral terms, starts with open questions, and follows with substance-specific details. Questions about peer environments, transportation, school, sports, social media contacts, buying pills, and coping should be concrete rather than accusatory. The teen is invited to describe both benefits they perceive in using and the harms they have noticed. Listening to these competing motivations is essential to collaborative care and does not require endorsing unsafe behavior.
Assessment also evaluates strengths: trusted adults, friendships, future goals, meaningful activities, school engagement, stable housing, community support, and willingness to return to appointments. A complete formulation integrates the substances involved, acute risks, degree of diagnostic certainty, mental and physical health, treatment preferences, caregiver capacity, and practical barriers. The ASAM youth criteria emphasize an individualized continuum and repeated reassessment rather than a single fixed placement decision.
Evidence-Based Treatment: What Has Actually Been Demonstrated?
The strongest contemporary synthesis is the AACAP guideline by Rockhill and colleagues, published online in 2025 and in the February 2026 journal issue. Using reviews and graded strength of evidence, it suggests specific psychosocial interventions for youth alcohol problems and illicit-drug disorders and longer-term buprenorphine treatment for opioid use disorder. These suggestions carry a relatively low strength-of-evidence rating, 2C, and the guideline finds insufficient evidence to make strong treatment claims for most other adolescent substance-disorder interventions. “Evidence-informed” should therefore be understood as a graded appraisal, not a guarantee that one method succeeds for every teenager.
Motivational interviewing and motivational enhancement
Motivational interviewing (MI) is a collaborative method for exploring ambivalence, personally meaningful goals, and motivation to change. In adolescent care, a brief intervention may help a young person recognize a hazardous pattern and agree to a next step; longer MI or motivational enhancement can form part of organized treatment. The AACAP guideline suggests brief MI for problematic alcohol use and nonbrief MI for alcohol-related problems, based on available trials. Effects vary by comparator, severity, substance, follow-up period, and whether a participant initially wants help. The method is most effective as part of a credible therapeutic relationship with follow-up, and should not be marketed as a universal cure.
Cognitive behavioral therapy
CBT approaches help teenagers identify patterns linking situations, thoughts, urges, emotions, substance access, and behavior, then rehearse coping and refusal skills, problem solving, emotion regulation, and relapse-prevention responses. AACAP suggests CBT for alcohol-related problems and CBT combined with more than brief MI for illicit-drug disorders. A 2024 systematic review of CBT in adolescent cannabis use disorder identified heterogeneous interventions and limited direct comparisons, underscoring that positive findings should not be turned into claims of clear superiority over every alternative treatment.
Family-based and systemic approaches
Family treatment may address communication, conflict, parental support, monitoring, safety planning, and practical treatment adherence. Established models include multidimensional family therapy, functional family therapy, and related systemic interventions. The AACAP guideline suggests nonbrief family therapy for alcohol problems with or without additional drug use. A systematic review of family therapy research found benefits for consumption and family functioning while acknowledging variation in study quality, populations, and intervention components. Family participation needs a safeguarding assessment: involving a harmful or abusive caregiver without protection may undermine care.
Combining behavioral interventions
Combined approaches are commonly adapted to the teen's substance profile, mental health conditions, school engagement, and relationship context. A 2024 meta-analysis of adolescent and young-adult alcohol treatment trials reported promising results for integrated motivational enhancement and CBT, but its pooled findings include varied age ranges and interventions. A systematic review of treatment mediators found limited evidence about precisely which proposed psychological mechanisms produce lasting behavior change. Clinicians should describe a method's observed outcomes separately from unproven mechanistic explanations.
Contingency management and other structured supports
Contingency management uses reinforcement for defined, verifiable therapeutic targets, such as attendance or changes in substance use. It has a stronger evidence base for certain adult disorders, especially stimulant disorders, than for universal use across adolescent SUDs. Youth-specific delivery requires attention to family context, incentives, feasibility, and fidelity to the tested intervention. Mutual-help groups, mentoring, recreation, recovery schools, and peer support can assist engagement, but their direct causal effects on adolescent substance use outcomes are unevenly studied. Digital apps and AI chatbots require separate assessment of clinical validation, safety, privacy, age appropriateness, and evidence compared with standard care; conversational fluency is not clinical effectiveness.
Medication Treatment and Substance-Specific Boundaries
Opioid use disorder
For adolescents with opioid use disorder, withholding evidence-based medication solely because of young age can leave a serious condition untreated. The AACAP guideline suggests longer-duration buprenorphine treatment rather than shorter treatment or rapid taper, with an age-appropriate clinical assessment and follow-up. Actual prescribing depends on jurisdiction, patient age, regulatory labeling, medical history, consent, and access to qualified care. Methadone, naltrexone, and buprenorphine have different regulations and evidence profiles for minors; choosing among them requires specialist evaluation. Naloxone addresses overdose risk and is not a maintenance treatment for opioid use disorder. Comprehensive care also addresses infectious disease risks, co-occurring conditions, family engagement, and social functioning.
Alcohol and sedatives
The first concern with heavy, sustained alcohol or benzodiazepine exposure is whether stopping abruptly may produce medically dangerous withdrawal. Withdrawal management can require monitored medical care. Its success should not be mistaken for completing treatment of the longer-term disorder. Adolescent evidence for many adult alcohol-use-disorder medications is sparse, and off-label use requires individualized specialist judgment. An adult evidence base cannot simply be applied to teenagers without assessing developmental differences, regulatory status, and the balance of benefits and harms.
Cannabis, nicotine, stimulants, and other substances
For adolescent cannabis use disorder, psychosocial care remains central, with medication approaches lacking a robust, approved disorder-specific evidence base. Nicotine use and vaping require age-appropriate assessment, behavioral support, and carefully individualized consideration of pharmacotherapy under pediatric guidance; the AACAP 2026 guideline explicitly excludes tobacco, so it cannot be cited as a nicotine treatment recommendation. Stimulant-related acute toxicity calls for urgent medical treatment when severe, while ongoing stimulant use disorder care emphasizes behavioral and psychosocial interventions. Inhalants may cause sudden serious toxic effects, and sedatives, polysubstance exposure, and emerging products each require their own clinical assessment. The teen-focused article identifies these pathways without duplicating the full substance-specific treatment guides.
Deciding Between Outpatient, Intensive, Residential, and Hospital Care
Treatment intensity is chosen according to medical stability, withdrawal and overdose risk, psychiatric danger, severity of the substance-related pattern, functional impairment, home safety, co-occurring needs, available supports, and the ability to engage reliably in follow-up. Many adolescents benefit from outpatient care that permits continued family, school, and community participation. More intensive outpatient or residential services may be indicated for severe or persistent risk when less intensive care cannot meet needs safely. Hospital-level care addresses acute poisoning, severe withdrawal, medical instability, or urgent psychiatric danger. Treatment setting is a clinical decision requiring ongoing reassessment, and residential placement alone does not establish superior long-term outcomes for every youth.
The ASAM Criteria, Fourth Edition youth volume, released in 2026, gives separate standards for adolescents and transition-aged youth. It incorporates integrated mental health care, family services, recovery support, risk reduction, and continuity after stabilization. The approach favors the least intensive setting capable of providing effective and safe care, matched to changing needs rather than to a single screening score.
Families: How to Respond Without Losing Communication
When a parent finds alcohol, pills, cannabis products, or evidence of vaping, the first task is to assess whether the teen needs immediate medical attention. Once immediate danger is excluded, choose a calm private time to discuss specific observations and the young person's perspective. State concrete health and safety concerns, invite an explanation, and arrange an evaluation with a pediatrician, adolescent medicine clinician, or age-appropriate addiction service when recurrent use, impairment, or concerning signs are present. Avoid turning the first conversation into an interrogation based only on suspicion.
Caregivers can support safer routines, monitor access to medicines and alcohol, address impaired driving and risky transportation, maintain predictable expectations, and participate in family intervention when clinically appropriate. Ask the care team how confidentiality will work and how to protect the teen's alliance with clinicians. Family involvement should expand the young person's access to safety and effective treatment, with additional protections when family conflict, neglect, abuse, or threats are present.
Harm Reduction and Immediate Risk Reduction
Some teens continue to use substances while assessment and treatment are underway. Harm reduction addresses preventable injury and death without delaying access to clinical treatment. An age-appropriate plan may include naloxone access for possible opioid exposure, education about counterfeit pills, avoiding impaired driving, urgent response to intoxication, safe storage of household medicines and alcohol, infection-prevention care when relevant, and proactive follow-up after nonfatal overdose. Naloxone should be available to people likely to witness an opioid overdose, with clear instructions to activate emergency services. Programs and legal protections differ across jurisdictions.
The CDC's 2026 fentanyl awareness materials emphasize substantial fentanyl involvement in fatal overdoses among young people ages 10–19 during 2020–2024. The figures concern overdose fatalities, not the proportion of all teenagers who use drugs. A focus on overdose safety must accompany, rather than replace, treatment of underlying substance use disorders and psychosocial needs.
Recovery, Remission, Recurrence, and Long-Term Functioning
Recovery in adolescence can involve reduced or discontinued substance use, improved physical and mental health, restored school engagement, safer relationships, stronger self-direction, and improved living circumstances. Remission is a formal diagnostic status under specified criteria; meaningful recovery extends into functioning, well-being, and participation. Recurrence of use or return of disorder symptoms may require treatment adjustment, reconsideration of medication or setting, attention to triggers, and renewed engagement. One return to use does not erase earlier functional gains or preclude future improvement.
Follow-up addresses substance use and overdose risk, sleep, mood, safety, family communication, education, and opportunities for purposeful activity. Transition to adult services can interrupt care, so clinicians plan continuity ahead of time. Goals should be collaborative, developmentally suitable, and responsive to changes in risk. For a separately scoped explanation of diagnostic status, see Can Substance Use Disorder Go Into Remission? Diagnosis and Prognosis.
Barriers to Access and Inequities in Care
Adolescents may avoid treatment because of stigma, fear that confidential information will reach caregivers or schools, transportation problems, cost, a shortage of youth-specialist services, family disruption, punitive responses, or uncertain eligibility. A 2024 systematic review of adolescent treatment access identified individual, social, gateway-provider, and service-level barriers, with substantial geographic gaps in the available studies. Clinicians can improve access by offering practical referral pathways, timely follow-up, confidentiality explanations, language access, coordinated mental health care, and telehealth where developmentally and clinically suitable.
Care must also account for discrimination, rural service shortages, involvement with child welfare or juvenile justice systems, homelessness, LGBTQ+ youth safety, disability-related communication needs, and adolescents living in unsafe households. These contextual factors influence exposure and access but should never become stereotypes or proxies for diagnosis. In high-risk situations, the immediate clinical duty is protection and connection to appropriate services.
What the Evidence Can and Cannot Tell Us
Established findings include the importance of rapid treatment for poisoning and overdose, the capacity of validated adolescent screening tools to identify risk, and the need to assess impairment and differential diagnoses before naming a disorder. Current clinical guidance supports selected psychotherapies and opioid medications, but the AACAP 2026 guideline graded multiple short-term treatment suggestions as 2C, reflecting limited certainty. This grade should accompany public descriptions of benefit. Research on family therapy and CBT offers useful direction while differing in intervention protocols, sample composition, outcome measures, and follow-up duration.
Preliminary or limited evidence covers many medication approaches outside adolescent OUD, long-term comparative superiority among youth psychotherapies, digital treatment tools, and exact treatment mechanisms. Conflicting public health recommendations on screening also reflect different questions: detection accuracy, feasibility, and whether universal preventive screening improves long-term health outcomes. Adult trial results, short adolescent follow-ups, samples restricted to treatment-seeking youth, and mixed adolescent–young adult cohorts can overstate how confidently findings apply to a 13-year-old in primary care. Clinical decisions must incorporate both research results and individual risk.
Frequently Asked Questions
Does experimenting with alcohol or cannabis mean a teen has addiction?
An episode of use establishes exposure. Diagnosis requires a clinically meaningful pattern meeting criteria for a particular disorder. Nevertheless, even a first exposure may cause poisoning, injury, or an overdose, so immediate safety assessment does not depend on an addiction diagnosis.
Which warning sign is the most reliable?
No single behavioral sign proves substance use. Direct disclosure, repeated intoxication episodes, documented hazards, impaired functioning, and substance-specific examination findings are more informative when interpreted together. A validated screen can identify the need for a fuller assessment.
Can a parent demand a drug test?
Legal authority, consent, and confidentiality depend on location and setting. Clinically, testing should answer a defined medical question and be interpreted with awareness of test limitations. Collaborative assessment and an explanation of why a test is proposed help preserve trust.
Will a positive CRAFFT score confirm substance use disorder?
No. CRAFFT estimates risk and indicates when further clinical assessment is appropriate. A clinician evaluates diagnostic criteria, substance type, frequency, consequences, co-occurring problems, and immediate danger.
Is a school suspension or residential placement a treatment?
Disciplinary action is not a validated medical treatment. Residential services can be appropriate for certain clinical needs, but placement should follow a multidisciplinary assessment of safety, severity, resources, and whether a less restrictive option can meet treatment goals.
Should teenagers stop alcohol or sedatives abruptly?
A teenager who may have developed physiological dependence on alcohol or benzodiazepines needs prompt medical advice, because abrupt withdrawal can lead to dangerous complications. Family members should seek professional assessment rather than designing an unsupervised discontinuation plan.
Can a teenager receive medication for opioid use disorder?
Yes, appropriate medications may be considered with age-specific, regulatory, consent, and specialist considerations. Current AACAP guidance supports buprenorphine treatment in adolescents and young adults with OUD, while recognizing limitations of youth-specific trial evidence. Emergency naloxone has a separate lifesaving overdose-reversal role.
What if the teenager refuses treatment?
Clarify immediate danger first. When there is no emergency, motivational conversation, repeated opportunities to engage, involvement of a trusted adult where safe, and a clear follow-up plan may improve access. Local laws govern consent and exceptional compulsory interventions. A respectful clinical relationship can remain useful even before a teenager agrees to a formal program.
Clinical Conclusion
Recognition and care for teen substance use disorders begin with a precise developmental question: what exposure has occurred, what harms and patterns are present, how safe is the young person today, and which supports will make effective care possible? Warning signs trigger inquiry. Screening structures risk identification. Diagnosis establishes a substance-specific clinical condition. Treatment combines age-appropriate psychosocial methods, indicated medications, family and community support, and ongoing reassessment. The current evidence supports selected interventions while leaving major knowledge gaps, making transparent discussion of evidence quality essential to ethical adolescent care.
Related Articles
Cluster Substance Use Disorders and Addiction Recovery — The scientific foundation for substance use disorders, diagnosis, mechanisms, treatment, and recovery.
Substance Use Disorder: Symptoms, Diagnosis, and Treatment — General clinical diagnosis and longitudinal treatment principles.
Substance Use Disorders and Suicide Risk: Evidence, Assessment, and Safety — Integrated clinical risk evaluation and safety planning.
Anxiety and Substance Use: Self-Medication, Withdrawal, and Comorbidity — A separate scientific examination of anxiety and substance involvement.
Can Substance Use Disorder Go Into Remission? Diagnosis and Prognosis — Diagnostic remission and long-term course.
References
American Academy of Pediatrics. (2016; reaffirmed 2023). Substance use screening, brief intervention, and referral to treatment. Pediatrics, 138(1), e20161211. https://doi.org/10.1542/peds.2016-1211
American Society of Addiction Medicine. (2026). The ASAM Criteria, Fourth Edition: Adolescents and Transition-Aged Youth Volume. https://www.asam.org/asam-criteria/adolescent-volume
Belay, G. M., et al. (2024). Psychosocial treatment options for adolescents and young adults with alcohol use disorder: Systematic review and meta-analysis. Frontiers in Public Health, 12, 1371497. https://doi.org/10.3389/fpubh.2024.1371497
Centers for Disease Control and Prevention. (2025). Fentanyl. https://www.cdc.gov/overdose-prevention/about/fentanyl.html
Centers for Disease Control and Prevention. (2026). National Fentanyl Awareness Day Toolkit. https://www.cdc.gov/overdose-prevention/php/toolkits/fentanyl-awareness-day.html
James, P. D., Nash, M., and Comiskey, C. M. (2024). Barriers and enablers for adolescents accessing substance-use treatment: A systematic review and narrative synthesis. International Journal of Mental Health Nursing, 33(6), 1687–1710. https://doi.org/10.1111/inm.13378
Knight, J. R., Sherritt, L., Shrier, L. A., Harris, S. K., and Chang, G. (2002). Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Archives of Pediatrics and Adolescent Medicine, 156(6), 607–614. https://doi.org/10.1001/archpedi.156.6.607
Mauries, S., et al. (2024). Cognitive-behavioral therapies in the management of adolescents with cannabis use disorder: A systematic review. Drug and Alcohol Dependence, 260, 111321. https://doi.org/10.1016/j.drugalcdep.2024.111321
Meisel, S. N., Pielech, M., Magill, M., Sawyer, K., and Miranda, R., Jr. (2024). Mechanisms of behavior change in adolescent substance use treatment: A systematic review of treatment mediators and recommendations for advancing future research. Clinical Psychology: Science and Practice, 31(2), 154–173. https://doi.org/10.1037/cps0000089
National Institute on Alcohol Abuse and Alcoholism. Alcohol Screening and Brief Intervention for Youth: A Practitioner's Guide. https://www.niaaa.nih.gov/alcohols-effects-health/professional-education-materials/alcohol-screening-and-brief-intervention-youth-practitioners-guide/resources
Rockhill, C. M., et al. (2026). Clinical practice guideline: Assessment and treatment of adolescents and young adults with substance use disorders and problematic substance use (excluding tobacco). Journal of the American Academy of Child and Adolescent Psychiatry, 65(2), 105–138. https://doi.org/10.1016/j.jaac.2025.08.006
Sulaman, I., Hartley, S., and Elvins, R. (2024). Therapeutic alliance in the treatment of adolescent substance misuse: A systematic review. Child and Adolescent Mental Health, 29(3), 226–241. https://doi.org/10.1111/camh.12671
United States Preventive Services Task Force. (2018). Unhealthy alcohol use in adolescents and adults: Screening and behavioral counseling interventions. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/unhealthy-alcohol-use-in-adolescents-and-adults-screening-and-behavioral-counseling-interventions
United States Preventive Services Task Force. (2020). Unhealthy drug use: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/index.php/recommendation/drug-use-illicit-screening